Edwards Lifesciences (NYSE:EW) Price Target Raised to $73.00

Edwards Lifesciences (NYSE:EW) had its price target lifted by Piper Sandler from $70.00 to $73.00 in a report issued on Wednesday,Benzinga reports. They currently have a neutral rating on the medical research company’s stock.

EW has been the topic of a number of other reports. Daiwa America downgraded Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 30th. Citigroup raised their target price on Edwards Lifesciences from $81.00 to $83.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. Wolfe Research lowered Edwards Lifesciences from a “peer perform” rating to an “underperform” rating and set a $60.00 price objective on the stock. in a report on Thursday, January 16th. Bank of America upgraded Edwards Lifesciences from a “neutral” rating to a “buy” rating and raised their target price for the stock from $82.00 to $90.00 in a research report on Monday, December 16th. Finally, The Goldman Sachs Group raised their target price on Edwards Lifesciences from $81.00 to $90.00 and gave the stock a “buy” rating in a research report on Thursday, December 5th. One equities research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat, Edwards Lifesciences presently has a consensus rating of “Hold” and an average target price of $79.95.

Edwards Lifesciences Trading Up 0.3 %

Shares of Edwards Lifesciences stock opened at $76.23 on Wednesday. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. The firm has a market cap of $44.96 billion, a price-to-earnings ratio of 11.00, a price-to-earnings-growth ratio of 3.64 and a beta of 1.10. The business has a fifty day simple moving average of $72.58 and a 200-day simple moving average of $69.41. Edwards Lifesciences has a fifty-two week low of $58.93 and a fifty-two week high of $96.12.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. On average, equities analysts forecast that Edwards Lifesciences will post 2.56 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, VP Daniel J. Lippis sold 2,500 shares of the business’s stock in a transaction on Monday, December 16th. The shares were sold at an average price of $74.08, for a total transaction of $185,200.00. Following the completion of the transaction, the vice president now directly owns 23,189 shares in the company, valued at $1,717,841.12. The trade was a 9.73 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Steven R. Loranger sold 5,739 shares of the company’s stock in a transaction on Friday, February 14th. The stock was sold at an average price of $76.42, for a total transaction of $438,574.38. Following the completion of the transaction, the director now owns 60,372 shares of the company’s stock, valued at $4,613,628.24. This trade represents a 8.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 26,489 shares of company stock valued at $2,002,829 in the last 90 days. 1.29% of the stock is currently owned by corporate insiders.

Institutional Trading of Edwards Lifesciences

Institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its stake in shares of Edwards Lifesciences by 10.4% during the fourth quarter. Vanguard Group Inc. now owns 69,132,036 shares of the medical research company’s stock valued at $5,117,845,000 after acquiring an additional 6,537,494 shares during the last quarter. Wellington Management Group LLP grew its holdings in Edwards Lifesciences by 5.3% in the fourth quarter. Wellington Management Group LLP now owns 33,210,879 shares of the medical research company’s stock worth $2,458,601,000 after purchasing an additional 1,678,154 shares during the period. State Street Corp grew its holdings in shares of Edwards Lifesciences by 1.0% during the third quarter. State Street Corp now owns 26,265,633 shares of the medical research company’s stock valued at $1,733,270,000 after buying an additional 256,538 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Edwards Lifesciences by 0.9% during the fourth quarter. Geode Capital Management LLC now owns 13,647,341 shares of the medical research company’s stock valued at $1,007,520,000 after buying an additional 126,194 shares during the last quarter. Finally, Fisher Asset Management LLC grew its holdings in shares of Edwards Lifesciences by 7.7% during the fourth quarter. Fisher Asset Management LLC now owns 9,775,276 shares of the medical research company’s stock valued at $723,664,000 after buying an additional 696,965 shares during the last quarter. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.